Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

Annalisa Cervone, Carla Giordano, Riccardo Bonadonna, Ivano Franzetti, Alessandra Dei Cas, Carla Giordano, Fabrizio Querci, Gian Pio Sorice, Vera Frison, Nino Cristiano Chilelli, Gaetano Leto, Giovanni Grossi, Gaetano Leto, Edoardo Duratorre, Carmela Vinci, Carlo Mannina, Giuseppe Capobianco, Federica D’Angelo, Giuseppe Saglietti, Massimiliano PetrelliGiuseppe Felace, Giuseppe Felace, Maurizio Poli, Maurizio Poli, Achiropita Pucci, Salvatore Piro, Salvatore Arena, Silvestre Cervone, Roberta Chianetta, Paola D’Angelo, Lucia Frittitta, Patrizia Li Volsi, Patrizia Li Volsi, Olga Lamacchia, Ioannis Karamouzis, Bruno Fattor, Raffaella Buzzetti, Alessandra Dei Cas, Paola Silvia Morpurgo, Gaetano Leto, Fadini, Ioannis Karamouzis, Natalino Simioni, Bruno Fattor, Roberto Anichini, Paola Silvia Morpurgo, Francesco Andreozzi, Gianluca Aimaretti, Ivana Zavaroni, Giuseppe Penno, Emanuela Orsi, Franco Cavalot, Susanna Morano, Antonino Di Benedetto, Enzo Bonora, Massimo Boemi, Giorgio Sesti, Angelo Avogaro, Annunziata Lapolla, Raffaella Buzzetti, Anna Solini, Riccardo Bonadonna, Massimo Cigolini, Antonio Carlo Bossi, Adriano Gatti, Agostino Consoli, Manfredi Rizzo, Giuliana Cazzetta, Giuliana Cazzetta, Gloria Formoso, Eleonora Devangelio, Eleonora Devangelio, Giorgia Lamacchia, Gustavo Mario Boemi, Luigi Grossi, Maria Rosa Morano

Risultato della ricerca: Articlepeer review

2 Citazioni (Scopus)

Abstract

Background and aims: In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM. Methods: The DARWIN-T2D was a multicenter retrospective study conducted at diabetes specialist outpatient clinics in Italy. We included 2484 patients who were initiated on dapagliflozin in 2015–2016 and 14,801 patients who were initiated on other GLM (DPP-4 inhibitors, GLP-1 receptor agonists, or gliclazide) in the same period. After excluding patients who had not (yet) returned to follow-up, we compared the characteristics of patients who persisted on drug versus those who were no longer on drug at the first available follow-up after at least 3 months. Results: As compared to those who persisted on drug, patients who discontinued dapagliflozin (51.7%) were more often female, had higher baseline fasting plasma glucose (FPG), HbA1c, and eGFR, and less common use of metformin. Upon multiple regression, higher HbA1c, higher eGFR, and lower metformin use remained independently associated with early discontinuation. Among patients who had been initiated on other GLM, 41.7% discontinued. Variables independently associated with discontinuation were older age, longer diabetes duration, higher HbA1c, eGFR, and albumin excretion, more common use of insulin and less metformin. Conclusion: In routine clinical practice, all variables associated with dapagliflozin discontinuation were also associated with discontinuation of other GLM. Thus, despite a distinctive mechanism of action and a peculiar tolerability profile, no specific predictor of dapagliflozin discontinuation was detected.
Lingua originaleEnglish
pagine (da-a)329-336
Numero di pagine8
RivistaJournal of Endocrinological Investigation
Volume43
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2712???
  • ???subjectarea.asjc.1300.1310???

Fingerprint

Entra nei temi di ricerca di 'Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study'. Insieme formano una fingerprint unica.

Cita questo